Anti-CGRP mAbs linked to spontaneous abortion

3 minute read


Researchers have called for women of childbearing potential to receive greater support and counselling before taking anti-CGRP monoclonal antibodies for the prevention of migraine.


A US-based retrospective cohort study has found women exposed to anti-CGRP monoclonal antibodies while pregnant had a 4.2% increase in their adjusted risk of spontaneous abortion by 20 weeks. 

The research, involving 7579 pregnancies among 7119 individuals, found the likelihood of spontaneous abortion in pregnant women exposed to anti-calcitonin gene-related peptides was 42% higher than unexposed women. The findings were published in JAMA Neurology.    

Researchers used data from an American administrative health insurance claims database that contained details on over two million pregnancies across the US between 2003 and 2021. Specifically, they focused on women aged 15 to 45 years with a singleton pregnancy who had held continuous health insurance from November 2018 onwards. Women who did not maintain their health insurance coverage were excluded.  

Exposure to anti-CGRP mAbs (erenumab, fremanezumab, galcanezumab, and eptinezumab) could occur from any point in the six months before their last menstrual period onwards. Women who used propranolol, another commonly used preventative medication for migraine, were included as a comparator group. 

Of the 7579 pregnancies, 350 were exposed to anti-CGRP mAbs, 283 were exposed to propranolol, and the remaining 6946 were unexposed to both treatments. There were 1862 spontaneous abortions during the study window, including 100 associated with anti-CGRP exposure and 37 associated with propranolol exposure. 

After adjusting for the effects of age, year of last menstrual period, pregestational comorbidities, gestational comorbidities, acute and preventative migraine drugs, other medication use, and healthcare utilisation, women exposed to anti-CGRP mAbs were 42% more likely (adjusted hazard ratio and 95% confidence interval 1.42, 1.12-1.80) to experience a spontaneous abortion compared to unexposed women. However, there was no such association for propranolol (aHR 1.02, 0.71-1.47).  

“Under a hypothetical scenario in which all pregnancies had anti-CGRP mAb exposure during pregnancy, the adjusted risk of spontaneous abortion by 20 weeks’ gestation was 28.7%, compared with 24.5% under no anti-CGRP mAb exposure,” the researchers noted. “This corresponded to an adjusted risk difference of 4.2 percentage points (95% CI, 2.4-9.6).” 

 

The researchers felt their findings added to the limited human evidence base regarding anti-CGRPs mAbs in pregnancy. 

“Prior pharmacovigilance studies have not identified a consistent association with adverse pregnancy outcomes, although exploratory drug-specific signals have been reported based on small numbers and may be affected by reporting bias,” they wrote. 

“Preclinical studies of erenumab in cynomolgus monkeys did not identify treatment-related effects on embryofetal development or fetal or infant loss, although exposure began after implantation, limiting assessment of early pregnancy loss. 

“Given CGRP’s role in uteroplacental vascular adaptation and placental development, an association with spontaneous abortion is biologically plausible.” 

While the researchers claimed the current study was the largest population-based study to examine the potential link between anti-CGRP mAb exposure and spontaneous abortion, their findings may not generalise beyond the commercially insured American women involved in the study.  

In addition, the researchers acknowledged the possibility that they underreported the number of spontaneous abortions in the current study, as other kinds of early pregnancy loss are not recorded in the administrative health dataset used in their analysis. 

They concluded by highlighting that further research into the safety of anti-CGRP mAbs for migraine prevention during pregnancy – including fetal and longer-term offspring outcomes – was required. 

“Until more evidence is available, clinicians should consider the limited evidence on pregnancy safety when discussing anti-CGRP mAb treatment with individuals who may become pregnant,” they said.  

JAMA Neurology, 12 October 2026 

End of content

No more pages to load

Log In Register ×